Biotricity Inc Cash Flow Conversion Efficiency
Biotricity Inc cash flow conversion efficiency. Based on the latest financial reports, Biotricity Inc (BTCY) has a cash flow conversion efficiency ratio of -0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($415.63K) by net assets ($-31.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biotricity Inc (2014–2025)
Cash flow conversion efficiency of Biotricity Inc from 2014 to 2025. This chart illustrates how Biotricity Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Biotricity Inc stock quote for real-time trading data and today's change.
Biotricity Inc Cash Flow Conversion Ratio Explained
Biotricity Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biotricity Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotricity Inc ranked by their cash flow conversion efficiency. Also see BTCY market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Silla Sg Co. Ltd
KQ:025870
|
0.474x |
|
Avalon GloboCare Corp.
NASDAQ:ALBT
|
-0.069x |
|
Global Sukses Solusi Tbk PT
JK:RUNS
|
-0.002x |
|
Pearl Polymers Limited
NSE:PEARLPOLY
|
-0.121x |
|
Atlantic Sapphire As
OL:ASA
|
-2.484x |
|
Zotefoams PLC
LSE:ZTF
|
0.044x |
|
Singularity Future Technology Ltd
NASDAQ:SGLY
|
-0.798x |
|
Marin Software Inc
NASDAQ:MRIN
|
-0.305x |
Annual Cash Flow Conversion Efficiency for Biotricity Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Biotricity Inc from 2014 to 2025. Review BTCY cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $-30.01 Million | $-2.38 Million | 0.079x | -64.49% |
| 2024-03-31 | $-29.98 Million | $-6.69 Million | 0.223x | -67.29% |
| 2023-03-31 | $-19.85 Million | $-13.55 Million | 0.683x | -90.34% |
| 2022-03-31 | $-2.14 Million | $-15.16 Million | 7.070x | +335.99% |
| 2021-03-31 | $-6.83 Million | $-11.08 Million | 1.622x | -38.12% |
| 2020-03-31 | $-3.00 Million | $-7.86 Million | 2.621x | -10.77% |
| 2019-03-31 | $-1.78 Million | $-5.22 Million | 2.937x | +110.44% |
| 2018-03-31 | $173.25K | $-4.87 Million | -28.136x | -3390.93% |
| 2017-03-31 | $-4.38 Million | $-3.75 Million | 0.855x | -46.06% |
| 2016-03-31 | $-1.24 Million | $-1.96 Million | 1.585x | +139.05% |
| 2015-03-31 | $340.00K | $-1.38 Million | -4.059x | -17150.20% |
| 2014-03-31 | $349.44K | $-8.22K | -0.024x | -- |
About Biotricity Inc
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux and Biocore Pro, an integrated ECG device and software that utilizes … Read more